Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experimental drug soquelitinib to treat patients with moderate to severe atopic dermatitis showed a favorable safety and efficacy profile.
The company said that patients receiving soquelitinib showed a 55.9% reduction in the Eczema Area and Severity Index score at 28 days compared to a 27% reduction in the placebo group.
It added that by day 58, the soquelitinib group continued to improve with a 69.1% mean Eczema Area and Severity Index reduction score, while the placebo group showed a 19.1% reduction.
The drug developer said no significant safety issues were observed during the study.
The company also said that Samlyn Capital, which holds warrants to purchase 3.6 million shares, has submitted exercise notices for all warrants before the June 30, 2025 expiration date to generate about $12.7 million in proceeds.
Shares were down over 33% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。